| 证券代码 | BIVV.O |
| 证券名称 | Bioverativ Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2017-02-02 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Bioverativ Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 225 Second Avenue, Waltham, Massachusetts, USA |
| 成立日期 | 2016-08-04 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.bioverativ.com |
| 电话 | +1 (781) 663-4400 |
| 传真 | - |
| 公司简介 | Bioverativ Inc. (NASDAQ: BIVV) is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. |